$NVS

$VYMI offers 3.3% dividend yield with 1,500+ stocks and 0.07% fees, outperforming S&P 500 with 24% annual returns for income-focused retirees.

Amphista Therapeutics presents three programs at AACR 2026, including oral presentation on AMX-883 BRD9 degrader for AML treatment.

Anaveon appoints veteran biotech executive Thaminda Ramanayake as CEO to guide lead candidate ANV200 through clinical development for autoimmune and inflammatory diseases.

Novartis presents 20+ abstracts at AAD 2026, highlighting rapid symptom relief with Rhapsido and long-term efficacy data for Cosentyx across multiple skin conditions.

Novartis acquires SNV4818, a next-gen PI3Kα inhibitor, from Synnovation for $2B upfront plus $1B milestones to treat PIK3CA-mutated breast cancer.

Amphista Therapeutics appoints new CEO and CMO ahead of planned AMX-883 IND application in April 2026 for acute myeloid leukemia treatment.

Novartis wins FDA approval for Cosentyx in pediatric hidradenitis suppurativa patients aged 12+, marking the drug's fourth pediatric indication and expanding its dermatology portfolio.

Biotech startup Unnatural Products secures $45M Series B funding led by The Venture Collective and inks $1.7B milestone deal with Novartis for oral peptide therapeutics.

Global skeletal dysplasia market projected to grow from $3.48B (2026) to $5.37B (2032) at 7.42% CAGR, driven by diagnostic advances and innovative therapies.

Global cytokines market projected to grow from $95.32B (2025) to $174.53B (2032) at 9.02% CAGR, driven by manufacturing advances and strategic partnerships.

American Kidney Fund launches "Kidneys Count" campaign March 1, 2026, promoting early detection and prevention of kidney disease affecting 1 in 7 American adults.

Advanced drug delivery systems market projected to grow from $299.6B (2025) to $487.4B (2030), driven by chronic diseases, nanotechnology breakthroughs, and oncology applications.

Global ophthalmic drug market projected to reach $41.88B by 2026, growing 7.9% annually driven by biologic therapies, advanced delivery systems, and AI-enabled diagnostics.

Novartis maintains growth despite patent challenges, backed by a strong product portfolio of 15 billion-dollar brands and nearly 30 years of consecutive dividend increases.

Novo Nordisk shares fell 16% after CagriSema obesity drug trial underperformed rival Eli Lilly's tirzepatide. Deutsche Bank downgraded the stock amid competitive concerns.

PYLARIFY becomes first radiodiagnostic to exceed $1 billion in annual sales with 24% growth, as PSMA-targeted prostate cancer treatments gain significant market momentum.

Turner Syndrome treatment market projected to double to $3.67B by 2033, driven by diagnostic innovation, increased awareness, and improved access to therapies globally.

Novartis's kidney drug Vanrafia shows sustained efficacy in slowing kidney function decline, supporting its path to full regulatory approval in 2026 for IgA nephropathy treatment.